265 results about "Ganglioside" patented technology

Engineered microparticles, libraries of microparticles, and methods relating thereto. The microparticles are distinguishable based on differences in dielectric response to an applied electric field. In different embodiments, the dielectric differences may be engineered through, but not limited to, dielectrically dispersive materials, surface charge, and / or fluorescence. Gangliosides may be incorporated with the microparticles to control aggregation. Vesicles including erythrocyte ghosts may be used as a basis for microparticles. The microparticles may utilize a biotin streptavidin system for surface functionalization.

Disclosed are infant formulas comprising fat, protein, carbohydrate, vitamins, and minerals, including on an as-fed basis, at least about 5 mg / L of gangliosides, at least about 150 mg / L of phospholipids, at least about 70 mg / L of total sialic acid with at least about 2.5% as lipid-bound sialic acid, at least about 0.13% docosahexaenoic acid by weight of total fatty acids, and at least about 0.25% arachidonic acid by weight of total fatty acids. Also disclosed are methods of accelerating brain development, neural migration, and cognitive development in an infant by administering the infant formulas during the first 2-4 months of life, preferably as a sole source of nutrition.

Human mesenchymal stromal cells can be induced to differentiate into oligodendrocytes and neurons, respectively. For these cell types, therefore, MSCs can be a therapeutic source, either in vitro or in vivo, in the context of treating pathologies of the central nervous system which are characterized by neuron loss, such as Parkinson's disease, Alzheimer's disease and stroke, as well as head trauma, or by dysfunction in ganglioside storage or demyelinization, such as Tay-Sachs disease, G1 gangliosidosis, metachromatic leukodystrophy, and multiple sclerosis.

Disclosed are infant formulas comprising fat, protein, carbohydrate, vitamins, and minerals, including on an as-fed basis (A) at least about 5 mg / L of gangliosides, (B) at least about 150 mg / L of phospholipids, and (C) lactoferrin, and (D) at least about 70 mg / L of sialic acid, with at least about 2.5% by weight of the sialic acid as lipid-bound sialic acid. Also disclosed are methods of using the formula to reduce the risk of diarrhea infants, and to produce a gut microflora profile similar to that of breast-fed infants.

The invention provides novel uses for n-glycolylated gangliosides and N-acetylated gangliosides, or derivatives and / or oligosaccharides thereof The invention further provides methods of obtaining such gangliosides, as well as vaccine compositions comprising said gangliosides. The gangliosides may be coupled to carriers and may be accompanied by adjuvants. The vaccine compositions can be used in the treatment of breast cancers, whereby the gangliosides are used to elicit an immune response to corresponding gangliosides on breast tumor cells.

This invention relates to specific antibodies against ganglioside GD3 called MB3.6 and against protein prostate specific membrane antigen (PSMA) called 3D8, 4D4 and 3E11 when prepared as chimeric molecules with signaling molecules of T cells and other effector cells, and the use thereof in the treatment of cancers expressing these antigens.

The invention provides formulations and methods for mediating inflammation, in particular an inflammatory bowel disorder such as necrotizing enterocolitis, and for. Further, the formulations are effective in lowering blood cholesterol and decreasing blood cholesterol absorption. The formulations comprise at least one ganglioside, which may be selected from the group consisting of: GD3, GM1, GM2, GM3, and GD1b. The invention provides a method of treating or preventing inflammatory diseases, such as necrotizing enterocolitis by delivery of at least one ganglioside to a subject in need thereof. Supplementation of foods or liquids with gangliosides, fore example infant formula or infant foods, can be employed according to the invention.

The present disclosure relates to nutritional compositions comprising a neurologic component, wherein, the neurologic component may promote brain and nervous system development and further provide neurological protection and repair. The neurologic component may include phosphatidylethanolamine, sphingomyelin, cytidine diphosphate-choline, ceramide, uridine, at least one ganglioside, and mixtures thereof. The disclosure further relates to methods of promoting brain and nervous system health by providing said nutritional compositions to target subjects, which includes pediatric subjects.

The present invention is related with the obtaining of modified antibodies by means of the DNA recombinant technology from the murine monoclonal antibody P3 (MAb P3) produced by the hybridoma cell line deposited under Budapest Treaty with accession number ECACC 94113026 and from its anti-idiotype murine monoclonal antibody 1E10(MAbai 1E10) produced by the hybridoma cell line with deposit number ECACC 97112901, with the objective of achieving monoclonal antibodies which preserve the biological function of specific binding to the antigen of the original antibodies, but being at the same time less immunogenic. The chimeric antibodies of the invention contain the variable domains of the murine immunoglobulin and the constant regions of the human immunoglobulin; and those humanized, besides containing the constant regions of the human immunoglobulins, they are modified in the region of the murine frameworks (FRs) and in particular in those zones that could be in an antigenic site for the T cells, so several positions of the FRS are human as well. These antibodies can be used in the diagnosis and therapy of different types of tumors. The present invention is also related with use of the antibodies for therapeutical and diagnostic purposes.

The present invention intends to provide a non-human animal model of Guillain-Barré syndrome, which can be obtained by immunizing FcγRIIB-gene-deficient non-human animal with ganglioside GQ1b, and a screening method of a therapeutic agent for Guillain-Barré syndrome using the non-human animal model. A mouse model of Guillain-Barré syndrome is generated by immunizing FcγRIIB-gene-deficient mice with gangliosides GM1, GM2, GD1a, and GQ1b together with Freund's adjuvant every three weeks four times in total.

A method for preparing the Monosialotetrahexosylganglioside with high purity is provided, which comprises the following process steps: (1) the fresh brain tissue of the licestock is used to prepare the acetone powder; (2) the acetone powder prepared in the step (1) is dissolved by the extracting solution and stirred for 4h to 5h, and is separated centrifugally and collects the supernatant, the supernatant is purified by LV chromatographic column to gain the total ganglioside; (3) the total ganglioside prepared in the step (2) is separated by MonoQ column chromatography to gain the ganglioside GM1 with purity of 90 per cent to 95 per cent; (4) the GM1 prepared in the step (3) is separated by the hydrophobic chromatography to gain the ganglioside GM1 with purity more than 98 per cent; (5) the GM1 aqueous solution prepared in the step (4) is hyperfiltrated by the hyperfiltration membrane with 50,000 to 100,000 MWCO, and the gained filter liquor produces the GM1 dry powder through freezing and drying. The method not only has simple process flow and safe operation, but also can improve the yield of the GM1 and avoid the pollution of other phospholipids.

Novel synthetic glycosphingolipids and pharmaceutical compositions containing such synthetic glycosphingolipids are described. Methods of making the novel synthetic glycosphingolipid compounds and compositions as well as their use in the field of neuroprotection and cancer treatment is also described.

In vitro / cell-free process of preparing a sialylated oligosaccharides are described. The sialylated oligosaccharides include gangliosides. The oligosaccharides linked to various moieties including sphingoids and ceramides. Novel compounds that comprise sphingoid groups are disclosed. The compounds include sialylated oligosaccharides including gangliosides as well as various sphingoids and ceramides.

Human mesenchymal stromal cells can be induced to differentiate into oligodendrocytes and neurons, respectively. For these cell types, therefore, MSCs can be a therapeutic source, either in vitro or in vivo, in the context of treating pathologies of the central nervous system which are characterized by neuron loss, such as Parkinson's disease, Alzheimer's disease and stroke, as well as head trauma, or by dysfunction in ganglioside storage or demyelinization, such as Tay-Sachs disease, G1 gangliosidosis, metachromatic leukodystrophy, and multiple sclerosis.

The present invention relates to monoclonal antibody 1A7. This is an anti-idiotype produced by immunizing with an antibody specific for ganglioside GD2, and identifying a hybridoma secreting antibody with immunogenic potential in a multi-step screening process. Also disclosed are polynucleotide and polypeptide derivatives based on 1A7, including single chain variable region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the 1A7 antibody overcomes immune tolerance and induces an immune response against GD2, which comprises a combination of anti-GD2 antibody and GD2-specific T cells. The invention further provides methods for treating a disease associated with altered GD2 expression, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell carcinoma. Patients who are in remission as a result of traditional modes of cancer therapy may be treat with a composition of this invention in hopes of reducing the risk of recurrence.

The invention provides infant formula milk powder for improving health of intestinal tracts, which is prepared with raw milk as a main raw material with addition of whey protein powder being rich in MFGM and other materials. By means of the novel whey protein powder being rich in MFGM as the raw material, contents of bio-active substances having special functional components, such as MFGM protein, lactoferrin, phospholipid, gangliosides, sphingomyelin, sialic acid and the like, are increased by regulation of the formula, so that the milk powder can promote colonization of probiotics in intestinal flora of infants and improves the content of immune factors in intestinal tracts and reduces intestinal disease incidence. The formula is suitable for researching on formula milk powder for infants and follow-up infants.

This invention comprises a recombinant protein comprising the maltose binding protein (MBP) of Escherichia coli fused to amino acids 5–337 of the FlaA flagellin of Campylobacter coli VC167 which has provided evidence of immunogenicity and protective efficacy against challenge by a heterologous strain of campylobacter, Campylobacter jejuni 81–176 in mammals. The invention further comprises a recombinant DNA construct encoding the immunodominant region (region I through III) of flagellin from Campylobacter spp. for use as a component of a vaccine against Campylobacter diarrhea. The invention therefore represents an effective treatment against Campylobacter but avoids inducing the autoimmune Guillain Barre Syndrome (GBS), a post-infection polyneuropathy caused by Campylobacter molecular mimicry of human gangliosides which has hampered the development of vaccines heretofore.

During the growth and study of NSCs, a range of molecules present on the surface of multipotent neural stem and progenitor cells (NSCs) were identified. These markers were identified using a number of human and murine neural stem cell lines, including retinal stem cells (RSCs). The NSC-specific markers identified included gene products as well as non-protein molecules and sugar epitopes not directly coded in the genome. Together with surface markers which were determined to be absent from the surface of hNSCs, the molecules described herein provide a means to enrich for neural stem cells, or neural progenitor subpopulations, particularly using combinatorial cell sorting strategies. These same molecules also represent targets for pharmacological manipulation of NSC populations and subpopulations, both in vivo and ex vivo. Furthermore, these molecules provide potential targets for therapeutic manipulation of other neural precursor-related cell types including malignant cell types as well as diseases originating from, or preferentially affecting, various uncommitted or replication-competent cell types.

The present invention generally provides compositions methods and composition relating to the diagnosis and / or treatment of cancers having a cell surface de-N-acetylated sialic acid antigen, e.g., an at least partially de-N-acetylated ganglioside and / or a de-N-acetylated sialic acid-modified cell surface protein.

The invention provides a preparation method for monosialotetrahexosyl ganglioside. The method comprises the following steps of: 1) weighing animal brain tissues, stirring and extracting by taking aqueous solution of a detergent as an extraction solvent and removing precipitate to obtain extract; and 2) concentrating the extract to obtain monosialotetrahexosyl ganglioside crude extract. The invention also provides a preparation comprising monosialotetrahexosyl ganglioside sodium. The preparation has the advantages of no use of organic solvent during the extraction of the monosialotetrahexosyl ganglioside, simple preparation process, suitability for batch production, environmental friendliness and capability of reducing the production cost and the production period. The invention also provides a monosialotetrahexosyl ganglioside injection prepared by the method; and the injection has high purity, does not contain an organic solvent and can improve the safety of clinical administration.

The monoclonal antibodies that only recognise the O-acetylated form of the GD2 ganglioside, or fragments of the antibody, for the diagnosis and the treatment of cancers in which the cells express the O-acetylated GD2, the antibody or the fragment recognising the O-acetylated GD2 molecules expressed by the tumoral cells and not recognising the GD2 molecules expressed at the surface of the peripheral nerves, in order to increase the specificity of the diagnosis and reduce the toxicity of the treatments. Also artificially modified antibodies advantageously used for treating and diagnosing cancers in which the cells express the O-acetylated GD2.

The invention relates to a preparation method of a nervous tissue repair scaffold loaded with dual trophic factors including ganglioside (GM1) and nerve growth factor (NGF). The method comprises the processes of constructing a preparation machine, preparing GM1 and NGF ultrapure water, preparing a hexafluoroisopropanol (HFIP) mixed solution of silk fibroin and polylactic acid-polycaprolactone (P(LLA-CL)), preparing the nanofiber scaffold loaded with the dual trophic factors including the GM1 and the NGF, and the like. The prepared nanofiber scaffold reforms a neural repair conduit through a biochemical method (namely addition of the active trophic factors) and a topological structure method (namely introduction of an oriented structure), aims to research the controlled-release behaviors and the nerve regeneration promotion function of the dual trophic factors, and can induce nerve regeneration through nanofiber orientation. The method provides experimental and theoretical basis for neural repair, and provides a new method for clinical repair of large nerve defects.

This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.

A process for preparing monosialic acid tetra-hexose ganglioside preparation from pig's brain includes such steps as ultrafilter membrane separation, chromatography by Iatrobeads column and DEAE sephadex A-25 column, and efficient liquid-phase chromatography technique. In the preparation process, it retains the GMI amphipathy physico-chemical characteristic of ganglioside. Its advantages are highpurity (more than 95%), low cost, environment protection and high curative effect.

One or more complex lipids including gangliosides to achieve particular health benefits including maintaining or increasing cognitive development or maintaining or increasing growth in a foetal, infant or child subject.

This invention describes unique patterns of distribution of ganglioside GM1 in non-capacitated sperm and demonstrates that the pattern of distribution of GM1 undergoes changes that can be correlated with the process of capacitation and / or with acrosomal exocytosis. Accordingly, the present invention discloses a method for determining the ability of sperm to respond to capacitation and / or acrosomal exocytosis stimuli. The method comprises determination of distribution pattern for GM1. The method can be used for both diagnostic and predictive purposes when assessing male reproductive fitness, and can also be used to assess the effects of any agent or environment on sperm including cryoprotective agents and protocols, and contraceptive agents.

The invention relates to a medicament for nerve regeneration promotion, and particularly to a nerve regeneration promotion injection and a preparation method thereof. The nerve regeneration promotion injection is composed of the following ingredients in proportion: 280-320 micrograms of mouse nerve growth factor for injection, 19-21ml of single sialic acid four hexose ganglioside sodium injecta, 18-22ml of cerebroside-kinin injecta, 9-11ml of mecobalamine injecta and 9-11ml of dexamethasone acetate injecta. The five effective ingredients of the medicament provided by the invention are combined together and cooperative actions of multiple nutritive factors are utilized, so that the medicament has a significant curative effect on repairing of injured nerve, especially the repairing of spinal nerve injury. The medicament provided by the invention also has a protection effect on spinal cord transected injury at the early stage.

The invention relates to high purity gangliosides preparation method. It includes the following steps: using higher animal brain cell as raw material; adding solvent to homogenate and do de-lamination; processing gnagliosides extracting solution by once new type macroporous resin column to gain the gangliosides which purity is more than 98%. The known gangliosides compound has extensive biological activity. And its main function is to cure and improve impaired neurological disease. The invention adopts new type macroporous resin for the first time, utilize resin structure to remove harmful substance, separate effective constituent, and keep its biological activity. It is fit for industrialization production.

The present invention relates to a medicine formed from ganglioside and ginkgo leaf extract and its healht-care product and application. The animal experiments and clinical trials show that the medicine and health-care product possess good synergistic action, and can obtain obvious effect for curing and preventing senile dementia, preventing and curing Parkinson's disease, curing and preventing ischemic cerebrovascular disease, and have the functions of delaying senility and raising resistance to fatigue and learning memory.